BioSpace News Archive

Patients with hypertension paired with a community health worker through their primary care practice were more than three and a half times as likely to achieve blood pressure control within six months compared to patients who were not.

BIOLASE, Inc., the global leader in dental lasers, announced the U.S. launch of the Waterlase Fractional Handpiece for doctors seeking a faster and more efficient way to perform skin resurfacing.

Immunocore Holdings plc (Nasdaq: IMCR) today announced that it will report full year 2022 results, before the US markets open on Wednesday, March 1, 2023.

IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, announced the ability of its novel non-signaling gamma-delta CAR-T platform (nsCAR) to selectively target leukemic cells while preserving healthy B cells.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for aflibercept 8 mg for treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy.

Aclaris Therapeutics, Inc. today announced its financial results for the fourth quarter and full year of 2022 and provided a corporate update.

Omega Therapeutics, Inc. today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 6,920,415 shares of common stock (the “Shares”) at a purchase price of $5.78 per share, resulting in gross proceeds of approximately $40 million.

Rafa Laboratories LTD. was awarded a follow-on production agreement for a total value of over $45 million from the Defense Department’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

Glooko Inc. (“Glooko”), today announced that they have entered into a partnering agreement with Sanofi to increase their support of people living with diabetes and healthcare professionals, by integrating SoloSmart with the Glooko® platform.

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.